Literature DB >> 28169483

Prognostic significance of combined albumin-bilirubin and tumor-node-metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma.

Norifumi Harimoto1, Tomoharu Yoshizumi1, Kazuhito Sakata1, Akihisa Nagatsu1, Takashi Motomura1, Shinji Itoh1, Noboru Harada1, Toru Ikegami1, Hideaki Uchiyama1, Yuji Soejima1, Yoshihiko Maehara1.   

Abstract

BACKGROUND: In recent years, the establishment of new staging systems for hepatocellular carcinoma (HCC) has been reported worldwide. The system combining albumin-bilirubin (ALBI) with tumor-node-metastasis stage, developed by the Liver Cancer Study Group of Japan, was called the ALBI-T score.
METHODS: Patient data were retrospectively collected for 357 consecutive patients who had undergone hepatic resection for HCC with curative intent between January 2004 and December 2015. The overall survival and recurrence-free survival were compared by the Kaplan-Meier method, using different staging systems: the Japan integrated staging (JIS), modified JIS, and ALBI-T.
RESULTS: Multivariate analysis identified five poor prognostic factors (higher age, poor differentiation, the presence of microvascular invasion, the presence of intrahepatic metastasis, and blood transfusion) that influenced overall survival, and four poor prognostic factors (the presence of intrahepatic metastasis, serum α-fetoprotein level, blood transfusion, and each staging system (JIS, modified JIS, and ALBI-T score)) that influenced recurrence-free survival. Patients for each these three staging system had a significantly worse prognosis regarding recurrence-free survival, but not with overall survival. The modified JIS score showed the lowest Akaike information criteria statistic value, indicating it had the best ability to predict overall survival compared with the other staging systems.
CONCLUSIONS: This retrospective analysis showed that, in post-hepatectomy patients with HCC, the ALBI-T score is predictive of worse recurrence-free survival, even when adjustments are made for other known predictors. However, modified JIS is better than ALBI-T in predicting overall survival.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  controlling nutritional status; hepatic resection; hepatocellular carcinoma; prognosis

Year:  2017        PMID: 28169483     DOI: 10.1111/hepr.12868

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  11 in total

1.  Wls Expression Correlates with Tumor Differentiation and TNM Stage in Hepatocellular Carcinoma.

Authors:  Chao Zhou; Yuejun Sun; Shuwei Guo; Xiao Chen; Genchong Bao; Jiandong Wang
Journal:  Dig Dis Sci       Date:  2017-11-10       Impact factor: 3.199

2.  [Plasma mannan?binding lectin and MBL?associated serine protease 2 in patients with hepatocellular carcinoma].

Authors:  Jie Li; Ling-Yan Zhu; Da-Ming Zuo; Li-Yun Zhang; Xiao Lu; Zheng-Liang Chen; Jia Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-12-20

3.  Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.

Authors:  In Soo Oh; Dong Hyun Sinn; Tae Wook Kang; Min Woo Lee; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Dig Dis Sci       Date:  2017-10-05       Impact factor: 3.199

4.  Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy.

Authors:  Linsen Ye; Rongpu Liang; Jiebin Zhang; Chaojin Chen; Xiaolong Chen; Yi Zhang; Guoying Wang; Yang Yang; Guihua Chen
Journal:  Ann Transl Med       Date:  2019-08

5.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.

Authors:  Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-09-22       Impact factor: 11.740

6.  RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma.

Authors:  Heng-Yuan Hsu; Ming-Chin Yu; Chao-Wei Lee; Hsin-I Tsai; Chang-Mu Sung; Chun-Wei Chen; Shu-Wei Huang; Cheng-Yu Lin; Wen-Juei Jeng; Wei-Chen Lee; Miin-Fu Chen
Journal:  BMC Cancer       Date:  2017-11-09       Impact factor: 4.430

7.  Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy.

Authors:  Xiu-Rong Cai; Zhan-Hong Chen; Meng-Meng Liu; Jin-Xiang Lin; Xiao-Ping Zhang; Jie Chen; Qu Lin; Xiao-Kun Ma; Jing-Yun Wen; Si-Dong Xie; Xiang-Yuan Wu; Min Dong
Journal:  J Cancer       Date:  2018-06-14       Impact factor: 4.207

8.  Effectiveness of the albumin-bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma.

Authors:  Yun Ho Lee; Yang Seok Koh; Young Hoe Hur; Chol Kyoon Cho; Hee Joon Kim; Eun Kyu Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-11-27

9.  The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy.

Authors:  Zhan-Hong Chen; Xiao-Ping Zhang; Xiu-Rong Cai; Si-Dong Xie; Meng-Meng Liu; Jin-Xiang Lin; Xiao-Kun Ma; Jie Chen; Qu Lin; Min Dong; Xiang-Yuan Wu; Jing-Yun Wen; Rui-Hua Xu
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

10.  A Novel Index in Hepatocellular Carcinoma Patients After Curative Hepatectomy: Albumin to Gamma-Glutamyltransferase Ratio (AGR).

Authors:  Junyi Shen; Li Tang; Xiaoyun Zhang; Wei Peng; Tianfu Wen; Chuan Li; Jiayin Yang; Guanjian Liu
Journal:  Front Oncol       Date:  2019-09-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.